Performance of omalizumab in patients with mast cell–mediated angioedema with and without wheals

The Journal of Allergy and Clinical Immunology In Practice 2026 Open access

Read full text
Authors: Sara van der Kamp, Reineke Soegiharto, Jennifer Astrup Sørensen, Ferhan Bulut Demir, Nasser Mohammad Porras, Yoshimi Matsuo, Lea Alice Kiefer, André C. Knulst, Marcus Maurer, Carla Ritchie, Michael Rudenko, Emek Kocatürk
+14 more Roberta Fachini Jardim Criado, Stamatios Gregoriou, Tatjana Bobylev, Andreas Kleinheinz, Shunsuke Takahagi, Michihiro Hide, Ana Maria Giménez‐Arnau, Andaç Salman, Rabia Öztaş Kara, Bahar Sevimli Dikicier, Martijn B. van Doorn, Simon Francis Thomsen, Juul M. P. A. van den Reek, Heike Röckmann
DOI: 10.1016/j.jaip.2026.03.004
Cited by: 0
References: 9

Abstract

Angioedema (AE) is characterized by recurrent, acute, and transient swelling of subcutaneous and mucosal tissues, often associated with a high patient burden.1 After exclusion of other mechanisms (eg, drug-induced, bradykinin-mediated, or endothelial dysfunction), the condition is classified as mast cell–mediated (AE-MC), a subtype of chronic spontaneous urticaria (CSU), and therefore managed according to urticaria guidelines. In patients without response to a daily 4-fold dose of antihistamines, add-on treatment with omalizumab (anti-IgE) is recommended.

Fields of Study & Subjects

Urticaria and Related Conditions Mast cells and histamine Coagulation Bradykinin Polyphosphates and Angioedema

Publication details

Journal / source
The Journal of Allergy and Clinical Immunology In Practice
Volume
14
Issue
6
Pages
1457–1460.e1
Publication date
12 March 2026
Language
EN